Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Duloxetine relieves pain in patients with chronic low back pain

10 Apr 2019

Treatment with duloxetine significantly reduces pain over 52 weeks in patients with chronic low back pain without new safety concerns, according to the results of a phase III trial.

The open-label phase III study included 150 patients (mean age 56.4 years; 53.3 percent female; mean weight, 62.6 kg) treated with 60-mg duloxetine once daily for 52 weeks.

Safety was evaluated based on adverse events (AEs), vital signs, laboratory test values, electrocardiogram, Columbia-Suicide Severity Rating Scale and occurrence of falls. Efficacy measures included the Brief Pain Inventory (BPI; average pain, worst pain, least pain and pain right now), BPI Interference, Patient’s Global Impression of Improvement (PGI-I), Clinical Global Impressions of Severity (CGI-S), Roland-Morris Disability Questionnaire–24 (RDQ-24), 36-Item Short-Form Health Survey (SF-36) and European Quality of Life-5 Dimensions Questionnaire (EQ-5D).

The incidence rate of AEs and adverse drug reactions (ADRs) were 86.1 percent and 50.3 percent, respectively. ADRs occurring in ≥5-percent of patients were somnolence, constipation, nausea and dry mouth. AEs led to treatment discontinuation in 16 patients.

In terms of efficacy, BPI average pain score significantly decreased from baseline at all time points: from week 2 (mean change, −1.02) to week 50 (mean change, −2.2). There were also improvements seen in BPI pain severity (worst pain, least pain and pain right now), BPI Interference, PGI-I, CGI-S, RDQ-24, SF-36 and EQ-5D.

The present data indicate that duloxetine is useful in the long-term treatment of patients with chronic low back pain, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.